Empowering Care,
One Heart at a Time

Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk.

The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease.

Our Mission Statement

Elucid’s mission is to predict and personalize the prevention of heart attacks and strokes.

At Elucid, we focus on enabling efficient and transparent clinical insights to help usher in the next generation of CCTA-guided, personalized coronary artery disease care. We develop AI tools to see invisible features of risk and guide personalized, precise treatment based on a detailed analysis of patients’ atherosclerotic disease. Elucid’s platform transforms CT images into a dynamic, interactive map of disease, providing a more precise view of atherosclerosis – the root cause of cardiovascular disease – to help physicians personalize care based on a patient’s individual anatomy.

A smiling couple walks arm-in-arm through a vibrant outdoor market full of fresh vegetables and flowers.

Elucid Leadership

Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller

Chief Technology Officer & SVP, Engineering
Windi Hary Chief Regulatory & Quality Officer

Windi Hary

Chief Regulatory & Quality Officer
Amy Kruglak SVP, People & Leadership Development

Amy Kruglak

SVP, People & Leadership Development
Amir Ahmadi, MD Lead Scientific Advisor

Amir Ahmadi, MD

Lead Scientific Advisor

News, Media & Thought Leadership

Stay informed with the latest updates, insights, and conversations from Elucid.
Type
News about Elucids PlaqueIQ™ being included in eviCore coverage guidelines, with text about coronary CTA plaque.

Elucid’s PlaqueIQ Image Analysis Software Included in EviCore Coverage Guidelines

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that EviCore, a radiology benefit manager, has updated its cardiac imaging guidelines to include coverage of coronary computed tomography angiography (CTA) plaque quantification (see pages 82-84), effective October 1, 2025.
News graphic announcing Elucids PlaqueIQ showcase at SCCT 2025, with a plaque diagram on the right.

Elucid to Showcase PlaqueIQ at SCCT 2025

Elucid will be featured along with its PlaqueIQTM image analysis software at the 20th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal.
News graphic announcing Dr. Robert Pelberg as SVP of Medical Affairs at Elucid, with his photo and credentials.

Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs

Elucid has named Dr. Robert “Bob” Pelberg as its new senior vice president of medical affairs.

Elucid Adds Clinical and Commercial Leadership Ahead of PlaqueIQ™ Launch

Elucid has added several senior members to its clinical and commercial teams.

Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule

Elucid has announced a final rule from US Centers for Medicare & Medicaid Services (CMS) that will significantly increase the reimbursement for cardiac computed tomography angiography (CCTA).
Curved modern building with many windows, set against a clear blue sky with a small white cloud.

Where to Find Us: Upcoming Events

Washington Hilton – Washington, DC – March 7-10, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Stay in Touch

Subscribe to our newsletter for the latest clinical, product and regulatory updates.

Eight people in an office sit and stand together, smiling and making heart shapes with their hands.